Literature DB >> 11012702

Synovectomy with rifampicine in haemophilic haemarthrosis.

F Fernandez-Palazzi1, S Rivas, R Viso, N B de Bosch, A R de Saez, A Boadas.   

Abstract

The purpose of this paper was to assess the effectiveness of intra-articular injected rifampicine in haemophilic patients in order to achieve synovectomy by preventing repeated intra-articular bleeding. We have used this technique in haemophilic patients previously and reported our results on 13 cases [1]. Two hundred and fifty milligrams of rifampicine was injected into the elbow and ankle joints and 500 mg was injected into knee joints with 3-10 mL of lidocaine, depending on the joint size. The injections were repeated once a week for 7 weeks. Patients were only covered with antihaemophilic factor on the day of the injection at 30% above their coagulation level. We evaluated the results using two measures: subjective reports from the patient and objective assessment by the examiner. In the subjective reports the patient graded the results from their own perspective from 1 (poor) to 10 (excellent): 1-3, poor; 4-6, fair; 7-8, good; and 9-10, excellent. In the objective reports the grading was: excellent ('dry joint', full function, no haemarthrosis, no synovitis); good (clinical improvement, synovitis, reduction of haemarthroses, full function); fair synovitis (reduction of haemarthroses, no change in function); poor synovitis (persistent haemarthroses). This paper reports on the results of 38 patients with 39 joints with more that 3 years follow up, mean 1.8 years. There were 22 knees, nine elbows and eight ankles. Subjectively, there were excellent results in 21 joints (11 knees, six elbows and four ankles) good results in 15 joints (eight knees, three elbows and four ankles), fair results in two knees and a poor result in one knee. Objectively, results obtained were excellent in 20 joints (11 knees, six elbows and three ankles); good in 17 (nine knees, three elbows and five ankles); fair in one knee and poor in one knee.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012702     DOI: 10.1046/j.1365-2516.2000.00411.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

Authors:  Junjiang Sun; Narine Hakobyan; Leonard A Valentino; Brian L Feldman; R Jude Samulski; Paul E Monahan
Journal:  Blood       Date:  2008-08-20       Impact factor: 22.113

2.  Synovitis and synovectomy in haemophilia.

Authors:  Lize F D van Vulpen; Sylvia Thomas; Swapnil A Keny; Shubhranshu S Mohanty
Journal:  Haemophilia       Date:  2020-06-03       Impact factor: 4.287

3.  Clinical and Radiological Evaluation After Chemical Synovectomy With Rifampicin in Hemophilic Arthropathy: Korean Experience With a 2-Week Interval Protocol.

Authors:  Hoon Chang Suh; Don-Kyu Kim; Si Hyun Kang; Kyung Mook Seo; Hee Sang Kim; Ji Young Lee; Sang Yoon Lee; Ki Young Yoo
Journal:  Ann Rehabil Med       Date:  2018-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.